Supplementary materials

Table S1: Risk of bias assessment of cross-sectional studies.

Components	Wu et al. 2023	Tamaki et al. 2023	Liu et al. 2023	Wang et al. 2022	Maeda et al. 2022	Li et al. 2022	Kocaoglu et al. 2022	Davison et al. 2022	Davran et al. 2022	Curran et al. 2021	Bai et al. 2021	Arfsten et al. 2021	Urbanowicz et al. 2020	Sadeghi et al. 2020	Turcato et al. 2019	Kone et al. 2019	Boralkar et al. 2019	Yurtdas et al. 2018	Yan et al. 2017	Pourafkari et al. 2017	Huang et al. 2017	Siniorakis et al. 2017	Yan et al. 2016	Wasilewski et al. 2016	Liu et al. 2016	Argan et al. 2016	Fu et al. 2015	Durmus et al. 2015	Cakici et al. 2014	Budak et al. 2014	Benites-Zapata et al. 2014	Turfan et al. 2013	Tasal et al. 2013	I I thamalingam et al 2010
1. Were the aims/o bjecti ves of the study clear?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Vec

| 2. Was the study design appro priate for the stated aim(s)? | Yes |
|---|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| 3. Was the sampl e size justifi ed? | Yes |

6. Was the selecti on proces s likely to select subjec ts/part icipan ts that were representati ve of the target/refere nce popul ation under investi gation?	Yes																																	
---	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

| 7. Were measu res undert aken to addres s and catego rize non-respon ders? | Not applicable |
|--|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|
| 8. Were the risk factor and outco me variab les measu red appro priate to the aims of the study? | Yes |

10. Is it clear what was used to deter mined statisti cal signifi cance and/or precisi on estima tes? (eg, p	Yes																																	
tes?																																		

| Were the metho ds (inclu ding statisti cal metho ds) suffici ently descri bed to enable them to be repeat ed? | Yes |
|---|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Were the basic data adequ ately described? | Yes |

| 13. Does the respon se rate raise concer ns about non-respon se bias? | No |
|---|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|
| 14. If appro priate, was infor matio n about non-respon ders described? | Not applicable |
| 15. Were the results intern ally consis tent? | Yes |

| 16. Were the results for the analys es described in the methods, presented? | Yes |
|--|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| 17. Were the author s' discus sions and conclu sions justifi ed by the results ? | Yes |

18. Were the limitat ions of the study discus sed?	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	No	Yes	Yes	Yes	No	Yes														
19. Were there any fundin g source s or conflicts of interes t that may affect the author s' interpretatio n of the results?	No	No	No	No	No	No	No	No	Νο	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No	No

20. Was ethical appro val or conse nt of partici pants attaine d?	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	No	No	Yes	No	Yes														
---	-----	-----	-----	-----	-----	----	-----	-----	-----	-----	-----	-----	----	-----	-----	----	----	-----	-----	-----	-----	-----	-----	-----	-----	----	-----	-----	-----	-----	-----	-----	-----	-----

Table S2: Risk of bias assessment of cohort studies.

Major components	Delcea et al. 2021	Angkananard et al. 2021	Kose et al. 2020	Cho et al. 2020	Zhu et al. 2022	Liu et al. 2022
1. Were the two groups similar and recruited from the same population?	Not applicable	Yes	Yes	Yes	Not applicable	Not applicable
2. Were the exposures measured similarly to assign people to both exposed and unexposed groups?	Not applicable	Not applicable	Yes	Yes	Not applicable	Not applicable
3. Was the exposure measured in a valid and reliable way?	Not applicable	Yes	Yes	Yes	Not applicable	Not applicable
4. Were confounding factors identified?	Yes	Yes	Yes	Yes	Yes	Yes
5. Were strategies to deal with confounding factors stated?	Yes	Yes	Yes	Yes	Yes	Yes
6. Were the groups/participants free of the outcome at the start of the study (or at the moment of exposure)?	Yes	Yes	Yes	Yes	Yes	Yes
7. Were the outcomes measured in a valid and reliable way?	Yes	Yes	Yes	Yes	Yes	Yes
8. Was the follow up time reported and sufficient to be long enough for outcomes to occur?	Yes	Yes	Yes	Yes	Yes	Yes
9. Was follow up complete, and if not, were the reasons to loss to follow up described and explored?	Yes	Yes	Yes	Yes	Yes	Yes
10. Were strategies to address incomplete follow up utilized?	Not applicable	Not applicable	Not applicable	Not applicable	Not applicable	Not applicable
11. Was appropriate statistical analysis used?	Yes	Yes	Yes	Yes	Yes	Yes

Overall appraisal:	Include	Include	Include	Include	Include	Include

Table S3. Heterogeneity results of included studies according to neutrophil to lymphocyte ratio.

Outcome of interest	Q^*	I^{2**}	τ ^{2***}	P
Mean NLR	3717.161	99.03%	1.167	<0.001
Total mortality	3465.655	99.27%	1.347	< 0.001
Follow-up mortality	2285.622	99.21%	1.132	< 0.001
In-hospital mortality	1456.922	99.38%	3.947	< 0.001
NLR difference (death/survival)	2589.33	98.95%	2.773	<0.001
NLR difference (HFpEF/HFrEF)	658.314	98.02%	1.05	<0.001

^{*:} Cochran's Q statistic for heterogeneity, **: Index for the degree of heterogeneity, ***: Tau-squared measure of heterogeneity.

NLR: neutrophil to lymphocyte ratio, HFpEF: heart failure with preserved ejection fraction, HFrEF: heart failure with reduced ejection fraction

Table S4. Certainty evidence of NLR difference in deceased compared to survived groups in HF patients.

			Certainty ass	sessment		Nº of p	atients	Effe	ct			
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Deceased	Survived	Relative (95% CI)	Absolute (95% CI)	Certainty	Importance
NLR diff	NLR difference											
13	observational studies	not serious	serious³	not serious	not serious	publication bias strongly suspected ^b	2299	5066	-	SMD 0.67 SD more (0.48 more to 0.87 more)	⊕○○○ Very low	IMPORTANT

CI: confidence interval; SMD: standardised mean difference

Explanations

- a. Considerable I2 value
- b. Evidence of publication bias using Duval and Tweedie's trim-and-fill method

Table S5. Certainty evidence of high NLR compared to low NLR for clinical outcomes in HF subjects.

			Certainty as	sessment			Nº of p	atients	Effec	:t		
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	High NLR	Low NLR	Relative (95% CI)	Absolute (95% CI)	Certainty	Importance
Mortality	hazard ratio											
6	observational studies	not serious	serious*	not serious	not serious	none			HR 1.77 (1.27 to 2.46)	2 fewer per 1,000 (from 2 fewer to 1 fewer)	⊕○○○ Very low	IMPORTANT
Death and	l/or re-hospitaliz	ation							•			•
5	observational studies	not serious	serious not serious not serious not serious none HF patients with higher NLR values had higher likelihood of death and/or readmission.							⊕⊕○○ Low	IMPORTANT	
HF predic	tion		•				•					•
4	observational studies	not serious	not serious	seriousb	not serious	none	One study was in	in favor of independ contrast to independer favor of independer	⊕○○○ Very low	IMPORTANT		
Extended	length of hospit	al stay	•									•
1	observational studies	not serious	not serious	not serious	not serious	none	Increased NLR was	as associated with h	nigher odds of increa	sed hospital	⊕⊕○○ Low	NOT IMPORTANT
Pulmonar	y resistance		•				-					•
1	observational studies	not serious	not serious	not serious	not serious	none		igher NLR had high ar systolic pressure	⊕⊕○○ Low	NOT IMPORTANT		
Atrial fibri	llation											
1	observational studies	not serious	not serious	not serious	not serious	none	NLR was an independent predictor of atrial fibrillation in HF patients.				⊕⊕○○ Low	NOT IMPORTANT
Renal dis	ease						•					•
2	observational studies	not serious	not serious	not serious	not serious	none	All studies reported NLR as an independent factor for renal disease.				⊕⊕○○ Low	NOT IMPORTANT
Functiona	l class											•
1	observational studies	not serious	not serious	not serious	not serious	none	NLR was an indep	pendent predictor of	poor functional clas	s in HF.	⊕⊕○○ Low	NOT IMPORTANT

CI: confidence interval; HR: hazard Ratio; NLR: neutrophil to lymphocyte ratio; HF: heart failure

Explanations

a. Considerable I2 value
 b. Studies with different reports.




Figure S1. Funnel plot for mean NLR based on total study population.




Figure S2. Funnel plot for mean NLR according to studies reported mortality (follow-up or in-hospital mortality).




Figure S3. Funnel plot for mean NLR according to studies reported follow-up mortality.




Figure S4. Funnel plot for mean NLR according to studies reported in-hospital mortality.




Figure S5. Funnel plot for mean NLR according to studies reported death or survived groups.




Figure S6. Funnel plot for NLR (as continuous variable) mortality hazard ratio.